Biogen news about the company’s decision to discontinue two Phase 3 Alzheimer’s drug studies is hitting BIIB stock hard on Thursday. Biogen (NASDAQ:BIIB) says that it will no longer be continuing with its Engage and Emerge studies. These studies were focusing on using aducanumab to treat patients that are suffering...